Use of Plasma with High Levels of lonised Calcium in the Production of Model Scale Goagulation Factor Concentrates

Summary

We have attempted to exploit the Ca²⁺ -dependent stability of factor VIII in producing factor VIII concentrates of higher yield. Plasma levels of ionised calcium were increased in two ways: (a) whole blood collection into half-strength citrate CPD anticoagulant, leading to free Ca²⁺ levels of ca 120 µM and (b) apheresis collection of plasma which was then recalcified to free Ca²⁺ levels of ca 300 µM under heparin cover. Coagulation factor concentrates were prepared using model versions of our industrial scale manufacturing methods. Factor VIII yield was increased through low citrate collection. This did not compromise factor IX yield or thrombogenic potential. Use of recalcified heparinised plasma did not lead to any improvement in factor VIII yield and resulted in a marked drop in factor IX recovery, possibly from interference by heparin of factor IX binding in ion-exchange chromatography. The benefits accruable through the use of half-strength citrate CPD anticoagulant support the continued evaluation of this preservative in large scale blood collection and fractionation. The deleterious effects of heparin in charge-mediated plasma fractionations may pose serious difficulties in harvesting vitamin K dependent factors.

• References

• 1 Weiss HJ. A study of the cation- and pH-dependent stability of factors V and VIII in plasma. Thromb Diath Haemorrh 1965; 14: 32-51
• 2 Rock GA, Cruickshank WH, Thckaberry ES, Palmer DS. Improved yields of factor VIII from heparinised plasma. Vox Sang 1979; 36: 294-230
• 3 Smit-Sibinga CTh, Welbergen H, Das PC, Griffin B. High yield method or production of freeze-dried purified factor VIII by blood banks. Lancet 1981; ii: 449-450
• 4 Morgenthaler JJ, Zuber I, Friedli H. Influence of heparin and calcium chloride on assay, stability and recovery of factor VIII. Vox Sang 1985; 48: 8-17
• 5 Godal HC. Precipitation of human fibrinogen with heparin. Scand J Clin Lab Invest 1960; 12: 56-65
• 6 Farrugia A. Studies on the procurement of blood coagulation factor VIII. PhD Thesis University of Edinburgh 1984
• 7 Prowse C, Waterson YG, Dawes J, Farrugia A. Studies on the procurement of blood coagulation factor VIII: in vitro studies on blood components prepared in half-strength citrate anticoagulant. Vox Sang 1987; 52: 257-64
• 8 Griffin B, Bell K, Prowse C. Studies on the procurement of blood coagulation factor VIII. In vivo studies on blood components prepared in half-strength citrate anticoagulant. Vox Sang 1988 54. 193-198
• 9 Lovric VA, Prince B, Bryant J. Packed red cell transfusions improved survival, quality and storage. Vox Sang 1977; 33: 346-52
• 10 Winkelman L, Owen NE, Evans DTR, Evans H, Haddon ME, Smith JK, Prince PJ, Williams JD, Lane RL. Severely heated therapeutic factor VIII concentrate of high specific activity. Vox Sang 1989; 57: 97-103
• 11 Farrugia A, Spiers D, Young I, Oates A, Herrington R, Damianos E. Effects of plasma collection systems and processing parameters on the quality of factor IX concentrate. Vox Sang 1989; 57: 4-9
• 12 Rowell JA, Elms MJ, Young J, Bunce IH. Automation of routine coagulation testing using a random access centrifugal analyzer. Am J Clin Pathol 1988; 89: 347-52
• 13 Kingdon HS, Lundblad RL, Veltkamp JJ, Aronson DL. Potentially thrombogenic materials in factor IX concentrates. Thromb Diath Haemorrh 1975; 33: 617-29
• 14 Sas G, Owens RE, Smith JK, Middleton S, Cash JD. In vitro spontaneous thrombin generation in human factor IX concentrates. Br J Haematol 1975; 31: 25-35
• 15 Farrugia A, Oates A, Spiers D, Young I, Herrington R. A microtitre plate test for assessment of in vitro thrombogenicity in factor IX concentrates using a chromogenic substrate. Thromb Res 1989; 53: 191-6
• 16 Giddings JC. The purification of factors VIII and IX and production of specific antisera. In: The Haemophilias Bloom AL. ed Churchill; Livingstone: 1982
• 17 de Jonge J, Smit Sibinga CTh, Das PC. Metabolic aspects and viability of heparin/CPDA-l stored red cell concentrate as a byproduct of a high yield factor VIII production method. Haemostasis 1983; 13: 214-9
• 18 Stathakis NE, Mosesson MW. Interactions among heparin, coldinsoluble globulin and fibrinogen in formation of the heparinprecipitable fraction of plasma. J Clin Invest 1977; 60: 855-65
• 19 Duguid J, Winkelman L, Feldman P, Brady AM. The effect of citrate anticoagulants on apheresed plasma. Tlansfus Sci 1989; l0: 287-93
• 20 Stibbe J, Hemker HC, vCreveld S. The inactivitation of factor VIII in vitro. Thromb Diath Haemorrh 1972; 43: 27-58
• 21 Mikaelsson ME, Forsman N, Oswaldsson UM. Human factor VIII: A calcium-linked protein complex. Blood 1983; 62: 1006-1015